Omega-3 fatty acids (EPA and DHA) have a real, decades-long research base in ADHD — but almost all of it is in children and adolescents, and even there the picture is mixed. Two influential meta-analyses found small but statistically significant improvements in attention and hyperactivity ratings12, while a more recent, more rigorous Cochrane review of 37 trials found little evidence that omega-3 outperforms placebo at all4. Where an effect does show up, it's consistently smaller than what stimulant or non-stimulant medication produces5. And research conducted specifically in adults with ADHD is thin — most of what exists on omega-3 and attention comes from pediatric trials that may or may not generalize to adult brains and adult-onset symptom patterns. This article lays out exactly what the studies found, what they didn't, and why Proco frames omega-3 as, at most, a modest adjunct alongside — never a substitute for — a clinical ADHD diagnosis, medication, or behavioral therapy.
What the pediatric research shows
The two most-cited meta-analyses on omega-3 and ADHD both come from children's trials, and both found a real but small effect.
Bloch and Qawasmi (2011) pooled 10 randomized trials in 699 children and found omega-3 supplementation produced "a small but significant effect in improving ADHD symptoms," with better outcomes at higher EPA doses. The authors were explicit that the effect was "modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α2 agonists" — their conclusion was that omega-3 might reasonably augment standard treatment, or serve as an option for families who decline medication, not replace it1.
Hawkey and Nigg (2014) extended that analysis to 16 trials and 1,408 children and adolescents, finding a composite symptom effect size of g = 0.26 — a small effect by conventional standards.
Where the newer evidence disagrees
Two more recent, larger reviews complicate the picture further — in opposite directions.
A 2023 meta-analysis in The Journal of Clinical Psychiatry pooled 22 RCTs and 1,789 children and adolescents. The overall effect on core ADHD symptoms was not statistically significant (SMD −0.16, 95% CI −0.34 to 0.01, p = 0.07). But when the researchers isolated trials that ran 4 months or longer, the effect became significant (SMD −0.35, 95% CI −0.61 to −0.09, p = 0.007) — suggesting that if omega-3 helps at all, it may take sustained use to show up, and short trials may simply be underpowered to detect it3.
Then, in the same year, an updated Cochrane review — generally considered the most rigorous form of evidence synthesis — pooled 37 trials and roughly 2,400 children and adolescents and reached a more skeptical conclusion: "little evidence that PUFA could improve ADHD symptoms such as inattention or hyperactivity-impulsivity," with high-certainty evidence of no effect on parent-rated total symptoms specifically4.
Two meta-analyses found a small, real effect. The most rigorous review to date found none. That's not a contradiction to paper over — it's the honest state of the evidence.
The adult evidence gap
Here's the part that matters most if you're an adult considering omega-3 for focus or attention: virtually none of the research above was conducted in adults. Bloch and Qawasmi's trials were in children. Hawkey and Nigg's were in children and adolescents. The 2023 Journal of Clinical Psychiatry meta-analysis and the 2023 Cochrane review were both restricted to children and adolescents. Even the NIH's National Center for Complementary and Integrative Health, summarizing the omega-3-and-ADHD literature for clinicians, discusses the evidence almost entirely in pediatric terms6.
That doesn't mean omega-3 doesn't do anything for adult attention — the underlying biology (DHA as a structural component of brain cell membranes, omega-3's role in neuronal signaling) doesn't stop applying at 18. But it does mean the specific claim "omega-3 improves ADHD symptoms" rests almost entirely on data from a different population, at different doses, over different study designs, and adult-specific randomized trial data is thin to the point of being close to absent. We'd rather say that plainly than imply the pediatric evidence transfers cleanly.
How omega-3 compares to ADHD medication
Scale matters here. Faraone and Glatt's 2010 meta-analysis of adult ADHD pharmacotherapy — 19 placebo-controlled trials across 13 medications — found effect sizes of roughly 0.73–0.96 for stimulant medications and roughly 0.39 for non-stimulants, depending on formulation5. Set next to that, omega-3's best-case pediatric effect size (g = 0.26) is smaller than even non-stimulant ADHD medication, and roughly a third of what short-acting stimulants produce. This is why every meta-analysis in this space — including the ones favorable to omega-3 — frames it as a possible complement to treatment, not a comparable alternative.
What this means if you have adult ADHD
ADHD in adults is a clinical diagnosis, made by a qualified professional, and the treatments with the strongest evidence behind them are medication and structured behavioral therapy. If you have — or suspect you have — adult ADHD, that's the evaluation and treatment path the evidence actually supports; nothing in this article is a substitute for it, and Proco doesn't market Omega-3 as one. If you're already on treatment and thinking about omega-3 as something additional, mention it to your prescriber first, particularly if you're on medication — read our breakdown of Cognitive Support and ADHD medication interactions for what to check before combining any supplement with a stimulant or non-stimulant prescription.
Proco's Omega-3 (180mg EPA + 120mg DHA per softgel) is dosed and disclosed for general cognitive support, not formulated or marketed as an ADHD treatment. Two softgels daily (the suggested use) deliver 360mg EPA and 240mg DHA — in range with the doses used across the pediatric trials above, though again, not tested in an adult-ADHD-specific trial. If focus and attention are the goal, worth reading first whether what you're actually dealing with is ADHD or burnout — the two look similar day to day but call for very different responses.
Bottom line
Omega-3's evidence base for ADHD symptoms is real but modest, built almost entirely on children and adolescents, and genuinely mixed even within that population — two meta-analyses found a small significant benefit, the most recent Cochrane review did not. Adult-specific RCT data barely exists. Where an effect shows up, it's consistently smaller than stimulant or non-stimulant medication. That makes omega-3, at best, a modest adjunct worth discussing with a clinician alongside standard care — never a stand-in for diagnosis, medication, or therapy.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(10):991-1000. pubmed.ncbi.nlm.nih.gov/21961774
- Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev. 2014;34(6):496-505. pubmed.ncbi.nlm.nih.gov/25181335
- Liu TH, Wu JY, Huang PY, et al. Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2023;84(5):22r14772. pubmed.ncbi.nlm.nih.gov/37656283
- Gillies D, Leach MJ, Perez Algorta G. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2023. pubmed.ncbi.nlm.nih.gov/37058600
- Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-763. pubmed.ncbi.nlm.nih.gov/20051220
- National Center for Complementary and Integrative Health. ADHD and Complementary Health Approaches: What the Science Says. nccih.nih.gov/health/providers/digest/adhd-science
Related reading: Cognitive Support and ADHD Medication: What to Know, Adult ADHD or Burnout? How to Actually Tell the Difference and ADHD and Sleep: Why They So Often Overlap
Want to know what's actually in what you take? Join the list — no spam, just it straight.